| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 12 Aug 2025 | 1 Aug 2025 |
| Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 inter alia to consider and approve unaudited financial results for the quarter ended on June 30 2025. Unaudited financial results for the quarter ended on June 30, 2025 (As Per BSE Announcement Dated on: 12/08/2025) | ||
| Board Meeting | 16 Jun 2025 | 16 Jun 2025 |
| Change in Senior Management | ||
| Board Meeting | 20 May 2025 | 9 May 2025 |
| Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 inter alia to consider and approve audited financial results for the quarter / year ended on March 31 2025 and to recommend final dividend for the financial year ended on March 31 2025. Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31, 2025 The Board also recommended final dividend of Rs. 11/- (@1100%) per equity share of Re. 1/- each, subject to approval of the shareholders at the ensuing Annual General Meeting scheduled to be held on August 12, 2025. (As Per BSE Announcement Dated on 20.05.2025) | ||
| Board Meeting | 11 Mar 2025 | 11 Mar 2025 |
| Acquisition of shares of Amplitude Surgical SA, France, a listed entity | ||
| Board Meeting | 5 Feb 2025 | 21 Jan 2025 |
| Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2025 inter alia to consider and approve unaudited financial results of the Company for the quarter / nine months ended on December 31 2024. Unaudited financial results for the quarter / nine months ended on December 31, 2024 (As Per BSE Announcement Dated on: 05/02/2025) | ||
| Board Meeting | 27 Dec 2024 | 27 Dec 2024 |
| Update on acquisition of a business | ||
| Board Meeting | 12 Nov 2024 | 30 Oct 2024 |
| Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve unaudited financial results for the quarter and half year ended on September 30 2024. Unaudited financial results for the quarter and half year ended on September 30, 2024 Unaudited financial results for the quarter and half year ended on September 30, 2024 (As Per BSE Announcement Dated on 12.11.2024) | ||
The company also announced that it has also received approval for generic furosemide tablets for veterinary use.
Here are some of the stocks that may see significant price movement today: Adani Enterprises, JSW Infrastructure, Zydus, etc.
Earlier this week, Zydus launched ‘VaxiFlu’, a trivalent influenza vaccine aligned with WHO guidelines, becoming the first Indian company to introduce such a vaccine.
The study, known as EPICS-III, tested the drug in adults with primary biliary cholangitis (PBC) a rare, progressive liver disease that often leaves patients with limited treatment options.
The company said it will work with the US regulator to resolve the points raised as quickly as possible.
This development comes after a USFDA inspection at one of Zydus' oncology facilities earlier this year.
In its filing with the bourses, Zydus informed that these observations received were minor, and not related to data integrity.
Here are some of the stocks that may see significant price movement today: Jio Financial Service, Hero MotoCorp, Abbott India, etc.
Here are some of the stocks that may see significant price movement today: Hindustan Copper, Maruti Suzuki, Zydus Lifesciences, etc.
For Zydus, this clean report adds a layer of credibility to its US compliance track record especially since the Ankleshwar facility is a key site for its API exports.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
